EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study

James D Doecke iD, Giovanni Bellomo, Lisa Vermunt, Daniel Alcolea, Steffen Halbgebauer, Sjors In 't Veld, Niklas Mattsson-Carlgren, Katerina Veverova, Christopher J Fowler, Lynn Boonkamp, Isabel M Houtkamp, Marleen Koel-Simmerlink und 24 weitere

Alzheimer's & Dementia · 2025-06 · 21 (6)

DOI: 10.1002/alz.14573 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 23.06.2025. Verfasst von James D Doecke und 35 weiteren Autor:innen. Beteiligte Einrichtung: Australian E-Health Research Centre, CSIRO, Herston, Queensland, Australia. Hauptthemen laut MEDLINE: tau Proteins, Amyloid beta-Peptides, Alzheimer Disease, Neurofilament Proteins. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, GHR Foundation, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Plasma phosphorylated tau (p‐tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non‐AD dementias in a large international multi‐center study. METHODS Plasma samples ( n = 1298) were collected from six international centers. Aβ40, Aβ42, GFAP, NfL, and p‐tau181 were measured using single molecule array. In each group, AD diagnosis/co‐pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut‐off models. RESULTS p‐tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aβ– dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre‐defined cut‐offs. DISCUSSION p‐tau181 was the best single plasma marker for detecting AD at any stage. Specific cut‐offs are needed to maximize diagnostic performances. Highlights Phosphorylated tau (p‐tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co‐pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co‐pathology in frontotemporal dementia (FTD), p‐tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAmyloid beta-PeptidesAlzheimer DiseaseNeurofilament ProteinsGlial Fibrillary Acidic ProteinPeptide FragmentsDementiaHumansFemaleMaleBiomarkersAgedPhosphorylationMiddle Aged

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid betadementia with Lewy bodiesfrontotemporal dementiaplasma biomarkers

Substanzen

tau ProteinsAmyloid beta-PeptidesNeurofilament ProteinsGlial Fibrillary Acidic Proteinneurofilament protein LBiomarkersPeptide FragmentsGFAP protein, humanamyloid beta-protein (1-42)amyloid beta-protein (1-40)

Autor:innen und Institutionen

  • Australian E-Health Research Centre, CSIRO, Herston, Queensland, Australia.
  • Section of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
  • Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands.
  • Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Department of Neurology, University of Ulm, Ulm, Germany.

ORCID-Profile: James D Doecke, Charlotte Teunissen

Förderung

  • European Research Council
  • GHR Foundation
  • Swedish Research Council
  • ERA PerMed
  • Knut and Alice Wallenberg foundation
  • Strategic Research Area MultiPark
  • Lund University
  • Swedish Alzheimer Foundation

Zitieren

APA

Doecke, J. D., Bellomo, G., Vermunt, L., Alcolea, D., Halbgebauer, S., In 't Veld, S., Mattsson-Carlgren, N., Veverova, K., Fowler, C. J., Boonkamp, L., Houtkamp, I. M., Koel-Simmerlink, M., Verberk, I. M. W., Gaetani, L., Toja, A., Wojdała, A. L., Fortea, J., Pijnenburg, Y., Lemstra, A., …, & Teunissen, C. (2025). Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study. Alzheimer's & Dementia, 21(6). https://doi.org/10.1002/alz.14573

Vancouver

Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, et al. Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study. Alzheimer's & Dementia. 2025;21(6). doi:10.1002/alz.14573

BibTeX
@article{Doecke2025,
  author = {Doecke, James D and Bellomo, Giovanni and Vermunt, Lisa and Alcolea, Daniel and Halbgebauer, Steffen and In 't Veld, Sjors and Mattsson-Carlgren, Niklas and Veverova, Katerina and Fowler, Christopher J and Boonkamp, Lynn and Houtkamp, Isabel M and Koel-Simmerlink, Marleen and Verberk, Inge M W and Gaetani, Lorenzo and Toja, Andrea and Wojdała, Anna Lidia and Fortea, Juan and Pijnenburg, Yolande and Lemstra, Afina and van der Flier, Wiesje and Hort, Jakub and Otto, Markus and Hansson, Oskar and Parnetti, Lucilla and Masters, Colin L and Lleó, Alberto and González-Escalante, Armand and Contador, José and Suárez-Calvet, Marc and Fernández-Lebrero, Aida and Puig-Pijoan, Albert and Ortiz-Romero, Paula and Jiménez-Moyano, Esther and Minguillón, Carolina and Del Campo, Marta and Teunissen, Charlotte},
  title = {Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {6},
  doi = {10.1002/alz.14573}
}
Kostenlos starten →